Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Veru Inc.

VERU ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$2.39

▲ +3.02%

Market Cap $40.75M · Vol 21.21K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$40.75M

Micro Cap

Div Yield

N/A

Quarterly dividend

EPS Growth

+34.52%

YoY

RSI (14)

32.50

Momentum

Beta

-1.16

vs Market

52W High

$7.32

68.31% below

52W Low

$2.05

13.17% above

Volume

21.21K

Avg 51.67K

P/B

3.04

Price-to-book

ROE

N/A

Return on equity

Free Float

90.78%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Veru Inc. (VERU) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does VERU pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.40%

-9.13%

-20.07%

-0.83%

YTD

+11.68%

-30.12%

-76.10%

-97.33%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-15,681,260.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-34.75% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.04
P/FCF	N/A
EPS Growth	+34.52%
Outstanding Shares	17.05M

Technical Indicators

50-Day SMA	$2.50
200-Day SMA	$2.49
RSI (14)	32.50
Beta	-1.16
52-Week High	$7.32
52-Week Low	$2.05

Volume Today	21.21K
Avg Daily Volume (30D)	51.67K
Relative Volume	0.41x
Volatility (10D)	34.90
Volatility (30D)	66.27
Free Float	90.78%

Analyst Consensus

STRONG BUY

Current Price $2.39

Mean Target $24.50

52W Low$2.05 52W High$7.32

Current

Target

$2.05 $7.32

Current Analyst target

+925.10% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SCF2T8

ISINUS92536C2026

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateDec 15, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +1.49% ARGX.BR argenx SE +2.29% ARGX argenx SE +1.13% INSM Insmed Incorporated +1.14% 2269.HK WuXi Biologics (Cayman) Inc. +0.32%

Company Profile

Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.